SynthesisFrontiers in immunology2025
Systematic review and meta-analysis of omalizumab for IgE-mediated food allergy in children and young adults.
Synthesis in Frontiers in immunology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Real-life lessons on omalizumab and food allergy: The potential for unexplored outcomes.The World Allergy Organization journal · 2026Review
- Almond Allergy in Children and Adults: A Narrative Review of Current Knowledge, Clinical Challenges, and Research Gaps.Nutrients · 2026Review
- Oral Immunotherapy-Induced Changes in IgE, IgG, and IgA: A Review of Antibody Isotype Shifts and Their Clinical Relevance in Food Allergy.Antibodies (Basel, Switzerland) · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objectives: This meta-analysis aims to evaluate the efficacy of omalizumab (as monotherapy or combined with OIT) in achieving target maintenance dose (TMD), and its safety profile in terms of treatment-emergent adverse events (TEAEs) and epinephrine use, in children and young adults with IgE-mediated food allergy. Methods: A comprehensive literature search was conducted across PubMed, Embase, Cochrane Library, and Web of Science databases to identify relevant randomized controlled trials (RCTs) and controlled clinical trials (CCTs). Eligible studies compared omalizumab-based interventions (monotherapy or OIT combination) with control strategies (placebo, placebo plus OIT, or strict allergen avoidance) in children and adolescents with IgE-mediated food allergy. The primary efficacy endpoint was the achievement of a target maintenance dose (TMD), defined as the maximum allergen dose tolerated without dose-limiting symptoms. Safety outcomes included the incidence of treatment-emergent adverse events (TEAEs) and the requirement for epinephrine administration. Data synthesis employed random-effects models to calculate pooled risk ratios (RRs) with 95% confidence intervals (CIs). Results: Eight studies (n = 734 participants) met the inclusion criteria, comprising 7 RCTs and 1 CCT. Pooled analysis demonstrated that omalizumab-based therapy significantly increased the likelihood of achieving a clinically meaningful TMD compared to control interventions (RR = 3.07, 95% CI: 1.42-6.62; p < 0.001), with consistent efficacy observed across subgroups of multiple food allergies, peanut allergy. With respect to safety, no statistically significant difference was noted in the overall incidence of TEAEs between the omalizumab and control groups (RR = 1.02, 95% CI: 0.74-1.41; p = 0.889). Similarly, the rate of epinephrine use during oral food challenges or treatment did not differ significantly between groups (RR = 0.59, 95% CI: 0.07-4.78; p = 0.099), though the wide confidence intervals indicate substantial uncertainty due to limited data. Conclusion: This meta-analysis provides robust evidence that omalizumab, either as monotherapy or in combination with OIT, significantly enhances allergen tolerance in children and young adults with IgE-mediated food allergy. Importantly, this therapeutic benefit is not accompanied by a significant increase in the overall burden of adverse events or epinephrine use relative to control strategies. Omalizumab thus represents a valuable therapeutic option for improving desensitization outcomes in this vulnerable population. Systematic review registration: https://www.crd.york.ac.uk/prospero/, identifier CRD420251087191.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.